The global market for Cancer Therapies was valued at US$210.5 Billion in 2024 and is projected to reach US$382.0 Billion by 2030, growing at a CAGR of 10.4% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Recent advancements in cancer therapies have introduced a new era of precision medicine, focusing on treatments that specifically target cancer cells while sparing healthy tissue. Immunotherapy, which leverages the body's immune system to fight cancer, has shown remarkable success in treating various types of cancer. Checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines are some of the innovative immunotherapy approaches that have gained approval in recent years. Additionally, targeted therapies that interfere with specific molecules involved in cancer growth and progression, such as tyrosine kinase inhibitors and monoclonal antibodies, have provided effective treatment options with fewer side effects compared to traditional methods. The advent of personalized medicine, where treatments are tailored based on the genetic profile of the patient’s tumor, has further enhanced the efficacy and safety of cancer therapies.
The growth in the cancer therapies market is driven by several factors. Advances in biotechnology and genomics have led to the development of novel therapies and personalized treatment approaches, significantly expanding the range of options available to patients. The increasing prevalence of cancer worldwide, partly due to aging populations and lifestyle factors, is fueling demand for effective treatments. Moreover, substantial investment in cancer research by pharmaceutical companies and government agencies is accelerating the discovery and development of new therapies. The rising awareness and early diagnosis of cancer are also contributing to market growth, as early-stage cancers are more treatable with modern therapies. Additionally, regulatory approvals of new and innovative treatments are providing more options for patients and clinicians. The expansion of healthcare infrastructure, particularly in emerging economies, is making advanced cancer therapies more accessible to a broader population. Collaborations and partnerships among biotech firms, research institutions, and healthcare providers are fostering innovation and facilitating the commercialization of cutting-edge cancer treatments.
Global Cancer Therapies Market - Key Trends & Drivers Summarized
Cancer therapies have evolved significantly over the past few decades, leading to improved patient outcomes and survival rates. Cancer therapy refers to the treatment of a patient suffering from cancer with therapies such as chemotherapy, targeted therapy, radiation therapy and immunotherapy among others. These treatments target the removal or destruction of cancerous cells. Surgery involves physically removing tumors, while chemotherapy uses potent drugs to kill rapidly dividing cells, and radiation therapy employs high-energy radiation to damage DNA in cancer cells, preventing them from multiplying. Given the side effects associated with these treatments, there has been a continuous search for more targeted and less harmful treatment options.Recent advancements in cancer therapies have introduced a new era of precision medicine, focusing on treatments that specifically target cancer cells while sparing healthy tissue. Immunotherapy, which leverages the body's immune system to fight cancer, has shown remarkable success in treating various types of cancer. Checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines are some of the innovative immunotherapy approaches that have gained approval in recent years. Additionally, targeted therapies that interfere with specific molecules involved in cancer growth and progression, such as tyrosine kinase inhibitors and monoclonal antibodies, have provided effective treatment options with fewer side effects compared to traditional methods. The advent of personalized medicine, where treatments are tailored based on the genetic profile of the patient’s tumor, has further enhanced the efficacy and safety of cancer therapies.
The growth in the cancer therapies market is driven by several factors. Advances in biotechnology and genomics have led to the development of novel therapies and personalized treatment approaches, significantly expanding the range of options available to patients. The increasing prevalence of cancer worldwide, partly due to aging populations and lifestyle factors, is fueling demand for effective treatments. Moreover, substantial investment in cancer research by pharmaceutical companies and government agencies is accelerating the discovery and development of new therapies. The rising awareness and early diagnosis of cancer are also contributing to market growth, as early-stage cancers are more treatable with modern therapies. Additionally, regulatory approvals of new and innovative treatments are providing more options for patients and clinicians. The expansion of healthcare infrastructure, particularly in emerging economies, is making advanced cancer therapies more accessible to a broader population. Collaborations and partnerships among biotech firms, research institutions, and healthcare providers are fostering innovation and facilitating the commercialization of cutting-edge cancer treatments.
Scope of the Study
The report analyzes the Cancer Therapies market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments:
Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Other Treatment Types); Cancer Type (Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer, Other Cancer Types).Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Chemotherapy segment, which is expected to reach US$112.8 Billion by 2030 with a CAGR of a 9.0%. The Targeted Therapy segment is also set to grow at 11.3% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $82.5 Billion in 2024, and China, forecasted to grow at an impressive 12.9% CAGR to reach $35.3 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AbbVie Inc., Alaunos Therapeutics, Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Cancer Therapies Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Cancer Therapies Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Cancer Therapies Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 109 major companies featured in this Cancer Therapies market report include:
- AbbVie Inc.
- Alaunos Therapeutics, Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bayer AG
- Bristol-Myers Squibb Company
- Celldex Therapeutics, Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- Glaxosmithkline Plc
- Johnson & Johnson Services, Inc.
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
Table of Contents
I. METHODOLOGYMII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned
- AbbVie Inc.
- Alaunos Therapeutics, Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bayer AG
- Bristol-Myers Squibb Company
- Celldex Therapeutics, Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- Glaxosmithkline Plc
- Johnson & Johnson Services, Inc.
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 590 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 210.5 Billion |
| Forecasted Market Value ( USD | $ 382 Billion |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 17 |
